Lilly Alimta Lung Cancer Use Supported By FDA Cmte.; Safety Profile Cited
Executive Summary
The favorable toxicity profile of Lilly's oncologic Alimta outweighs uncertain survival benefits in the second-line treatment of non-small cell lung cancer, FDA's Oncologic Drugs Advisory Committee agreed July 27
You may also be interested in...
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Genta Genasense NDA In Myeloma Or Leukemia Slated For Year-End Filing
Genta is shifting its Genasense development focus to multiple myeloma and chronic lymphocytic leukemia with the goal of submitting an NDA for one of the oncology indications by year-end